Lithium Treatment Is Safe in Children With Intellectual Disability
Lithium is a widely used and effective treatment for individuals with psycho-neurological disorders, and it exhibits protective and regenerative properties in multiple brain injury animal models, but the clinical experience in young children is limited due to potential toxicity. As an interim analys...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Molecular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnmol.2018.00425/full |
id |
doaj-38253b75d06c4e80975de116b4f62fa9 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Junying Yuan Juan Song Dengna Zhu Erliang Sun Lei Xia Xiaoli Zhang Chao Gao Galila Agam Xiaoyang Wang Xiaoyang Wang Klas Blomgren Klas Blomgren Changlian Zhu Changlian Zhu |
spellingShingle |
Junying Yuan Juan Song Dengna Zhu Erliang Sun Lei Xia Xiaoli Zhang Chao Gao Galila Agam Xiaoyang Wang Xiaoyang Wang Klas Blomgren Klas Blomgren Changlian Zhu Changlian Zhu Lithium Treatment Is Safe in Children With Intellectual Disability Frontiers in Molecular Neuroscience intellectual disability cognition lithium safety children |
author_facet |
Junying Yuan Juan Song Dengna Zhu Erliang Sun Lei Xia Xiaoli Zhang Chao Gao Galila Agam Xiaoyang Wang Xiaoyang Wang Klas Blomgren Klas Blomgren Changlian Zhu Changlian Zhu |
author_sort |
Junying Yuan |
title |
Lithium Treatment Is Safe in Children With Intellectual Disability |
title_short |
Lithium Treatment Is Safe in Children With Intellectual Disability |
title_full |
Lithium Treatment Is Safe in Children With Intellectual Disability |
title_fullStr |
Lithium Treatment Is Safe in Children With Intellectual Disability |
title_full_unstemmed |
Lithium Treatment Is Safe in Children With Intellectual Disability |
title_sort |
lithium treatment is safe in children with intellectual disability |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Molecular Neuroscience |
issn |
1662-5099 |
publishDate |
2018-11-01 |
description |
Lithium is a widely used and effective treatment for individuals with psycho-neurological disorders, and it exhibits protective and regenerative properties in multiple brain injury animal models, but the clinical experience in young children is limited due to potential toxicity. As an interim analysis, this paper reports the safety/tolerability profiles of low-dose lithium treatment in children with intellectual disability (ID) and its possible beneficial effects. In a randomized, single-center clinical trial, 124 children with ID were given either oral lithium carbonate 6 mg/kg twice per day or the same dose of calcium carbonate as a placebo (n = 62/group) for 3 months. The safety of low-dose lithium treatment in children, and all the adverse events were monitored. The effects of low-dose lithium on cognition was evaluated by intelligence quotient (IQ), adaptive capacity was assessed by the Infant-Junior Middle School Students Social-Life Abilities Scale (IJMSSSLAS), and overall performance was evaluated according to the Clinical Global Impression-Improvement (CGI-I) scale. After 3 months of lithium treatment, 13/61 children (21.3%) presented with mild side effects, including 4 (6.6%) with gastrointestinal symptoms, 4 (6.6%) with neurological symptoms, 2 (3.3%) with polyuria, and 3 (4.9%) with other symptoms—one with hyperhidrosis, one with alopecia, and one with drooling. Four children in the lithium group had elevated blood thyroid stimulating hormone, which normalized spontaneously after lithium discontinuation. Both IQ and IJMSSSAS scores increased following 3 months of lithium treatment (F = 11.03, p = 0.002 and F = 7.80, p = 0.007, respectively), but such increases were not seen in the placebo group. CGI-I scores in the lithium group were 1.25 points lower (better) than in the placebo group (F = 82.66, p < 0.001) after 3 months of treatment. In summary, lithium treatment for 3 months had only mild and reversible side effects and had positive effects on cognition and overall performance in children with ID.Clinical Trial Registration: Chinese Clinical Trial Registry, ChiCTR-IPR-15007518. |
topic |
intellectual disability cognition lithium safety children |
url |
https://www.frontiersin.org/article/10.3389/fnmol.2018.00425/full |
work_keys_str_mv |
AT junyingyuan lithiumtreatmentissafeinchildrenwithintellectualdisability AT juansong lithiumtreatmentissafeinchildrenwithintellectualdisability AT dengnazhu lithiumtreatmentissafeinchildrenwithintellectualdisability AT erliangsun lithiumtreatmentissafeinchildrenwithintellectualdisability AT leixia lithiumtreatmentissafeinchildrenwithintellectualdisability AT xiaolizhang lithiumtreatmentissafeinchildrenwithintellectualdisability AT chaogao lithiumtreatmentissafeinchildrenwithintellectualdisability AT galilaagam lithiumtreatmentissafeinchildrenwithintellectualdisability AT xiaoyangwang lithiumtreatmentissafeinchildrenwithintellectualdisability AT xiaoyangwang lithiumtreatmentissafeinchildrenwithintellectualdisability AT klasblomgren lithiumtreatmentissafeinchildrenwithintellectualdisability AT klasblomgren lithiumtreatmentissafeinchildrenwithintellectualdisability AT changlianzhu lithiumtreatmentissafeinchildrenwithintellectualdisability AT changlianzhu lithiumtreatmentissafeinchildrenwithintellectualdisability |
_version_ |
1725900931202023424 |
spelling |
doaj-38253b75d06c4e80975de116b4f62fa92020-11-24T21:46:38ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992018-11-011110.3389/fnmol.2018.00425396960Lithium Treatment Is Safe in Children With Intellectual DisabilityJunying Yuan0Juan Song1Dengna Zhu2Erliang Sun3Lei Xia4Xiaoli Zhang5Chao Gao6Galila Agam7Xiaoyang Wang8Xiaoyang Wang9Klas Blomgren10Klas Blomgren11Changlian Zhu12Changlian Zhu13Henan Key Laboratory of Child Brain Injury, Department of Child Rehabilitation, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Child Brain Injury, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Child Brain Injury, Department of Child Rehabilitation, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Child Brain Injury, Department of Child Rehabilitation, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Child Brain Injury, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Child Brain Injury, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Child Rehabilitation, Children’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Mental Health Center, Ben-Gurion University of the Negev, Beersheba, IsraelHenan Key Laboratory of Child Brain Injury, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaPerinatal Center, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenDepartment of Women’s and Children’s Health, Karolinska Institutet, Stockholm, SwedenPediatric Hematology and Oncology, Karolinska University Hospital, Stockholm, SwedenHenan Key Laboratory of Child Brain Injury, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaCentre for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenLithium is a widely used and effective treatment for individuals with psycho-neurological disorders, and it exhibits protective and regenerative properties in multiple brain injury animal models, but the clinical experience in young children is limited due to potential toxicity. As an interim analysis, this paper reports the safety/tolerability profiles of low-dose lithium treatment in children with intellectual disability (ID) and its possible beneficial effects. In a randomized, single-center clinical trial, 124 children with ID were given either oral lithium carbonate 6 mg/kg twice per day or the same dose of calcium carbonate as a placebo (n = 62/group) for 3 months. The safety of low-dose lithium treatment in children, and all the adverse events were monitored. The effects of low-dose lithium on cognition was evaluated by intelligence quotient (IQ), adaptive capacity was assessed by the Infant-Junior Middle School Students Social-Life Abilities Scale (IJMSSSLAS), and overall performance was evaluated according to the Clinical Global Impression-Improvement (CGI-I) scale. After 3 months of lithium treatment, 13/61 children (21.3%) presented with mild side effects, including 4 (6.6%) with gastrointestinal symptoms, 4 (6.6%) with neurological symptoms, 2 (3.3%) with polyuria, and 3 (4.9%) with other symptoms—one with hyperhidrosis, one with alopecia, and one with drooling. Four children in the lithium group had elevated blood thyroid stimulating hormone, which normalized spontaneously after lithium discontinuation. Both IQ and IJMSSSAS scores increased following 3 months of lithium treatment (F = 11.03, p = 0.002 and F = 7.80, p = 0.007, respectively), but such increases were not seen in the placebo group. CGI-I scores in the lithium group were 1.25 points lower (better) than in the placebo group (F = 82.66, p < 0.001) after 3 months of treatment. In summary, lithium treatment for 3 months had only mild and reversible side effects and had positive effects on cognition and overall performance in children with ID.Clinical Trial Registration: Chinese Clinical Trial Registry, ChiCTR-IPR-15007518.https://www.frontiersin.org/article/10.3389/fnmol.2018.00425/fullintellectual disabilitycognitionlithiumsafetychildren |